Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Aug 13, 2021 9:00pm
197 Views
Post# 33705406

The Authors

The Authors
Below is the list of the authors of the article so these are folks with extended knwoledege in biochemistry, drug discovery…
 
Michel Demeule, Ph.D.
PROFILE
Drug discovery researcher with over 20 years of experience in the academic and the pharmaceutical industry; highly effective, collaborative, passionate and a dynamic scientist who enjoys the challenge of scientific research and appreciates the ability to drive projects in an environment that encouraged teamwork. Has worked on all aspects of drug transport and brain delivery of molecules, including small molecules, peptides, monoclonal antibodies and antibody drug conjugates in oncology and other CNS diseases.
 
Cyndia Charfi
Senior Coordinator, Research chez Theratechnologies Inc
Senior Research Associate
UQAM's Chair in Cancer Prevention and Treatment in collaboration with Theratechnologies
 
 
 
Jean-Christophe Currie
Senior Scientist, Oncology at Theratechnologies Inc
 
Alain Larocque
Chief Chemistry at Theratechnologies Inc
About
I am a peptide chemist with over 31 years of experience in the biotechnology sector, specifically in peptide chemistry. My hallmark is total quality and, over the years, I have acquired an exceptionally wide range of skills including the design, launch and management of laboratories; development of synthesis processes; design and manufacturing of research equipment; drafting of standard operating procedures as part of a quality assurance program, etc. Finally, my broad fields of interests, inter-personal skills and extensive network represent a key asset to devise innovative and informed solutions when faced with various scientific and business issues.
 
Specialties: Peptide synthesis, Organic synthesis, Purification by Prep HPLC or Silica (Biotage/Combi-flash) and MS-QTOF / MALDI-TOF, Fixing pretty much everything !
 
Alain Zgheib
https://www.researchgate.net/profile/Alain-Zgheib
 
 
Sophie Kozelko
Laboratory Technician in-vivo - Pharmacology
UQAM | Universit du Qubec Montral
 
Richard Bliveau
Academic title(s): 
Full Member, McGill Centre for Translational Research in Cancer
Emeritus professor, Universit du Qubec Montral
Scientific Director, Chair in Cancer Prevention and Treatment, Universit du Qubec Montral
Associate researcher, Segal Cancer Center, Lady Davis Institute for Medical Research
 
Christian Marsolais
Dr. Christian Marsolais has been Senior Vice President and Chief Medical Officer since June 2016. He joined Theratechnologies in 2007. He brings more than 30 years of experience in the research, development and commercialization of new drugs.
He started his career working for global pharmaceutical companies, including Sandoz (now Novartis), Biochem and Pfizer. Prior to joining Theratechnologies, he was part of the global oncology team at Pfizer.
 
Borhane Annabi
PhD Biochemistry, Universit du Qubec Montral
January 1999 - Present
Department
Department of Chemistry
Location
Montral, Canada
Position
Professor (Full)
 
<< Previous
Bullboard Posts
Next >>